Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-07
2006-03-07
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S267000
Reexamination Certificate
active
07008947
ABSTRACT:
Disclosed are compounds of the formulaand the pharmaceutically acceptable salts thereof where the variables R1, R2, A, R4, R5, R6, R6′, n, and W are defined herein. These compounds bind to the benzodiazepine site of GABAAreceptors are provided and, therefore can be used to modulate ligand binding to GABAAreceptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals.
REFERENCES:
patent: 4950585 (1990-08-01), Tachibana et al.
patent: 2003/0176450 (2003-09-01), Atkinson et al.
patent: 0 591 528 (1994-04-01), None
patent: 0 795 555 (1997-09-01), None
patent: 2 157 285 (1985-10-01), None
Albaugh Pamela
Li Guiying
Peterson John
Berch Mark L.
McDonnell Boehnen & Hulbert & Berghoff LLP
Neurogen Corporation
LandOfFree
(Oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3613798